Protocol
09-005
Full Title
A Randomized Trial of Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy
Purpose
When a bilateral nerve-sparing radical prostatectomy is performed as treatment for prostate cancer, it may take 12 to 24 months before a patient recovers normal erectile function. The concept of penile rehabilitation revolves around using medications to cause erections, promoting erectile tissue protection while the nerves repair themselves.
The aim of this study is to evaluate the effectiveness of two new approaches for improving erectile function recovery in patients after radical prostatectomy: nightly sildenafil (Viagra®) versus penile injections therapy alternating with sildenafil, or the current standard of care, sildenafil taken before planned intercourse. Patients will be randomly assigned to one of three treatment groups.
Investigator
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a confirmed diagnosis of prostate cancer and be scheduled for bilateral nerve-sparing radical prostatectomy.
- Patients must be in a stable sexual relationship for at least six months.
- Patients must not be planning preoperative or postoperative pelvic radiation therapy or hormonal therapy.
- Patients must be age 18 or older.
For more information and to inquire about eligibility for this study, please contact Dr. John Mulhall at 646-442-4410.
Disease(s)
Prostate Cancer
Prostate Cancer: Quality of Life
Survivorship
Locations
ClinicalTrials.gov
Related Diseases
